Tsao David sold $2.2M of BLLN

Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $109.24 ($107.31–$113.16, $2.18M total) across 14 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Nov 5, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale may trigger short‑term selling pressure, but the long‑term impact depends on BLLN's pipeline and financing needs.

02

Market read

Insider sales are closely watched by traders; a $2.2M sale by a C‑level officer is noteworthy for short‑term sentiment.

03

What to watch

Potential upcoming financing rounds or dilution that prompted the 10b5‑1 plan, which may offset the negative signal.

Relevance 5/10Novelty 5/10Timing: post-filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering timely insight into executive sentiment.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

SEC Form 4 shows CTO Tsao David sold 20,000 shares (~$2.2M) of BillionToOne, Inc., reducing his stake to 1,000 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A 10b5-1 planned sale of a sizable position by the CTO signals possible concerns about valuation or upcoming dilution, which typically weighs on the stock.

Market effects

Minimal; the sale is company‑specific and does not affect the broader biotech sector.

None; the filing is U.S. SEC‑based with no regional spillover.

Low; only relevant to investors tracking BLLN.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, and the remaining 1,000 shares still align interests.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on Nasdaq under ticker BLLN.

  • Tsao David

    Chief Technology Officer of BillionToOne, filing the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.